Reply to Volkman et al. Comment on "Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434"

被引：0
|
作者：
Kohli, Michele [1 ]
Joshi, Keya [2 ]
Beck, Ekkehard [2 ]
Hagiwara, Yuriko [3 ]
Van de Velde, Nicolas [2 ]
Igarashi, Ataru [4 ]
机构：
[1] Quadrant Hlth Econ Inc, 92 Cottonwood Crescent, Cambridge, ON N1T 2J1, Canada
[2] Moderna Inc, 325 Binney St, Cambridge, MA 02142 USA
[3] Moderna Inc, 4-1-1 Toranomon,Kamiyacho,Minato Ku, Tokyo 1056923, Japan
[4] Univ Tokyo, Grad Sch Pharmaceut Sci, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan
来源：
VACCINES | 2024年 / 12卷 / 10期
关键词：
coronavirus; SARS-CoV-2; Japan; COVID-19; vaccination; cost-effectiveness;
D O I：
10.3390/vaccines12101175
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Reply to letter of Davie et al. regarding the article: "Vitamin D concentrations and COVID-19 infection in UK Biobank" (Hastie et al.)
    Pell, Jill P.
    Hastie, Claire E.
    Sattar, Naveed
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (02) : 642 - 642
  • [12] Unheard voices: The impact of the COVID-19 pandemic on disordered eating in people with marginalized identities: Commentary on Devoe et al. (2022), Linardon et al. (2022) and Schneider et al. (2022)
    Mikhail, Megan Elizabeth
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2023, 56 (01) : 68 - 71
  • [13] "ISTH guidelines for antithrombotic treatment in COVID-19": Comment from Huisman et al.
    Huisman, Menno V.
    Klok, Frederikus A.
    Kamphuisen, Pieter W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (11) : 2708 - 2709
  • [14] The proportion of COVID-19 cases that are asymptomatic in South Korea: Comment on Nishiura et al.
    Workman, Joseph
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 96 : 398 - 398
  • [15] Reply to Spreco et al.: Perceived corruption and preferences for COVID-19 vaccine allocations
    Duch, Raymond
    Robinson, Thomas S.
    Clarke, Philip M.
    Roope, Laurence S. J.
    Violato, Mara
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (19)
  • [16] Authors’ Reply to Vrachatis et al. “Pharmaco-Immunomodulatory Therapy in COVID-19”
    John G. Rizk
    Kamyar Kalantar-Zadeh
    Mandeep R. Mehra
    Carl J. Lavie
    Youssef Rizk
    Donald N. Forthal
    Drugs, 2020, 80 : 1501 - 1503
  • [17] Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19"
    Davoudi-Monfared, Effat
    Khalili, Hossein
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (04)
  • [18] Reply to Jacobs et al.: Massive transfusion protocols during the COVID-19 pandemic
    Chang, Chih-Chun
    Sun, Jen-Tang
    VOX SANGUINIS, 2022, 117 (06) : 870 - 871
  • [19] Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy in COVID-19"
    Rizk, John G.
    Kalantar-Zadeh, Kamyar
    Mehra, Mandeep R.
    Lavie, Carl J.
    Rizk, Youssef
    Forthal, Donald N.
    DRUGS, 2020, 80 (14) : 1501 - 1503
  • [20] REPLY TO DUSHOFF ET AL. AND PIFARR ′ E I AROLAS ET AL.: Age prioritization for COVID-19 vaccination does save lives and years of life
    Goldstein, Joshua R.
    Cassidy, Thomas
    Wachter, Kenneth W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (29)
12345